Evidence map›Paper›PMID 42438210›Full record

ReviewBioEssays : news and reviews in molecular, cellular and developmental biology2026

PHLPP is neither a Phosphatase nor a Tumor Suppressor.

Thomas A Leonard

Abstract readReview
In one paragraph

Review in BioEssays : news and reviews in molecular, cellular and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Thomas A LeonardMax Perutz Labs, Medical University of Vienna, Vienna, Austria.

Funding

Austrian Science Fund P33066
6 · The paper itself

Abstract

PH domain leucine-rich repeat protein phosphatases 1 and 2 (PHLPP1/PHLPP2) have, for more than 20 years, been described as Akt phosphatases and tumor suppressor genes. Approximately 200 PubMed-indexed articles have been published on the topic, including efforts to pharmacologically inhibit PHLPP in disease settings. A recent study, however, presents evidence that PHLPP is actually a pseudophosphatase with no catalytic activity. These observations question its reported role in cancer. The designation of PHLPP1 and PHLPP2 as pseudophosphatases necessitates both a critical examination of the literature and new hypotheses for the biological function of these ancient proteins. Here, we review the emergence of PHLPP1 and PHLPP2 as cellular signal transducers, critically examine the evidence for their reported phosphatase activity and tumor suppressor functions, and propose steps to elucidate their biological functions.

Indexed as

Nuclear ProteinsPhosphoprotein PhosphatasesAnimalsGenes, Tumor SuppressorHumansNeoplasmsProto-Oncogene Proteins c-aktSignal TransductionTumor Suppressor ProteinsNuclear ProteinsPHLPP1 protein, humanPHLPP2 protein, humanPhosphoprotein PhosphatasesProto-Oncogene Proteins c-aktTumor Suppressor ProteinsAkt signallingcancercell biologykinasemembranePHLPPphosphatasephylogeneticsProtein Kinase Btumor suppressor gene

Identifiers

PMID42438210
PMCPMC13358185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.